Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Amgen and Novartis discontinue Alzheimer’s drug development programme

pharmaceutical-technologyJuly 17, 2019

Tag: Amgen , Novartis , Alzheimer’s drug

PharmaSources Customer Service